A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Hydroxychloroquine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 24 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 15 Jun 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016, according to ClinicalTrials.gov record.